查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950546

1型高雪氏症治疗市场（依治疗类型、患者年龄、治疗阶段、通路及最终用户划分），全球预测，2026-2032年

Type 1 Gaucher Disease Treatment Market by Treatment Type, Patient Age, Line Of Therapy, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 1 型高雪氏症治疗市场在 2025 年的价值为 23.4 亿美元，在 2026 年成长至 25.7 亿美元，到 2032 年达到 49.8 亿美元，复合年增长率为 11.39%。

关键市场统计数据
基准年 2025 23.4亿美元
预计年份：2026年 25.7亿美元
预测年份 2032 49.8亿美元
复合年增长率 (%) 11.39%

本书清晰地介绍了影响 1 型高雪氏症治疗决策的临床复杂性、治疗实施挑战以及相关人员的需求。

由于其慢性且临床表现复杂，治疗方法高度专业化，1 型高雪氏症在罕见疾病治疗领域占据特异性的地位。患者依赖酵素替代疗法和基材减少疗法，这些疗法需要持续的临床监测和整合式护理路径。因此，临床医生、支付方和生产商必须紧密合作，以确保治疗的连续性，同时兼顾安全监测、输液物流和患者的长期支持需求。

临床创新、分散式服务模式以及不断变化的支付方期望如何重塑罕见疾病治疗的模式和营运重点

1型高雪氏症的治疗格局正在经历变革性变化，这主要得益于临床创新、以患者为中心的医疗服务模式以及不断变化的监管环境和报销要求。新型小分子疗法的出现为口服治疗带来了可能，使临床医生和患者能够考虑终身输液治疗以外的其他选择。同时，生物製药生产和製剂技术的进步正在提高供应链的稳健性和产品的稳定性，从而实现更多样化的分销和给药模式。

随着关税变化与特殊生物製药和小分子药物供应链相互交织，并影响治疗交付，营运韧性和策略采购变得愈发重要。

计划于2025年在美国实施的新关税，将为依赖国际供应链和特殊生产投入的治疗方法带来额外的营运和财务复杂性。对于需要特殊辅料的生物製药和治疗方法的生产而言，关税带来的成本压力可能会影响供应商选择、筹资策略和库存计划。因此，製造商及其物流合作伙伴正在寻求供应商多元化，重新评估近岸外包方案，并重新审视合约条款，以减轻跨境贸易变化的影响。

将治疗方法、医疗机构、通路、人口统计特征和治疗方案与临床和营运影响联繫起来的多维度细分方法

这种市场细分为解读1型高雪氏症治疗的临床选择和治疗模式提供了一个系统性的观点。基于治疗类型，市场研究涵盖酵素替代疗法（ERT）和基材减少疗法（SRT）。酵素替代疗法进一步细分为伊米苷酶、他利苷酶α和维拉苷酶α。基材减少疗法进一步细分为依利格鲁司他和米格鲁司他。这种以治疗为中心的市场区隔有助于阐明作用机制、给药途径和监测要求如何影响医护人员的选择和病患的依从性。

区域治疗可近性和获取差异揭示了医疗保健结构和报销框架如何影响世界各地治疗的采用和护理模式。

地理因素影响临床实务模式、报销环境和营运限制，进而影响1型高雪氏症的诊疗方式。美洲地区通常拥有专业中心和完善的家庭输液及专科药房基础设施，有利于在门诊和家庭环境中进行长期管理。这些区域特征支援整合式诊疗路径，但也需要专科药局、输液护理师和专科医护人员之间密切合作。

成熟的生物製药组合和新兴的口服疗法透过供应链弹性、病患服务和实证医学证据，推动了竞争优势的差异化。

1型高雪氏症治疗领域的竞争格局呈现出成熟生物製药与新兴小分子疗法并存的局面，各公司致力于透过提高生产可靠性、完善患者支持服务以及积累真实世界证据来实现差异化。拥有传统酵素疗法的公司持续投资于产品生命週期策略，例如提升产品稳定性、优化给药便利性以及透过患者支援计画扩大患者可及性。这些措施旨在确保患者长期治疗的连续性，同时满足医疗服务提供者和支付者的新营运需求。

将临床创新与具有韧性的供应链、分散式交付和基于结果的支付方参与相结合的切实战略重点

罕见疾病治疗领域的领导企业应优先考虑整合临床证据、交付能力和支付方合作的整合策略，以确保永续的医疗服务可近性和最佳的患者疗效。首先，应投资于端到端供应链的韧性，透过多元化采购、检验替代製造地以及加强低温运输可视性来降低中断和关税相关影响。加强与供应商的关係并提高合约柔软性将有助于跨地区和跨医疗机构提供持续的医疗服务。

采用透明的混合研究途径，结合专家访谈、文献综述和案例研究，以得出可复製的实用结论。

本分析所依据的研究结合了严谨的质性分析和结构化的综合方法，以确保获得可靠且可操作的洞见。主要研究包括对溶小体储积症专科临床医生、输液服务管理护士长、负责特药分发的药房主任以及患者权益倡导组织代表的深度访谈，他们提供了关于治疗经历和依从性障碍的第一手观点。此外，还咨询了采购、监管和报销方面的专家，以了解营运和政策方面的情况。

整合临床、营运和策略要务凸显了协调一致的创新、具有韧性的交付系统以及相关人员协作参与的必要性。

总之，1型高雪氏症的治疗格局呈现出临床细微差别、供应创新和运作复杂性交织的特征。酵素替代疗法和基材减少疗法的治疗选择与患者年龄、治疗方案和护理环境密切相关，从而形成高度个人化的治疗路径。同时，供应分散、专科药房生态系统日趋成熟以及贸易趋势带来的供应链压力，进一步凸显了製定更具韧性的营运策略的必要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 1型高雪氏症治疗市场（依治疗方法）

  • 酵素替代疗法
    • 伊米苷酶
    • Taliglucerase alfa
    • Velaglucerase alfa
  • 基材减少疗法
    • Eliglustat
    • 米格鲁司他

9. 依患者年龄分類的1型高雪氏症治疗市场

  • 成人版
  • 儿童

10. 1型高雪氏症治疗市场（依治疗线划分）

  • 一线治疗
  • 二级治疗

11. 按分销管道分類的1型高雪氏症治疗市场

  • 居家输液
  • 医院药房
  • 专科药房

12. 依最终用户分類的1型高雪氏症治疗市场

  • 居家医疗环境
  • 医院
  • 点滴中心

13. 各地区1型高雪氏症治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 1型高雪氏症治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国1型高雪氏症治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国1型高雪氏症治疗市场

第十七章 中国1型高雪氏症治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amicus Therapeutics, Inc.
  • AVROBIO, Inc.
  • CANbridge Life Sciences Ltd.
  • CHIESI Farmaceutici SpA
  • Dr. Reddy's Laboratories Ltd.
  • Evotec SE
  • Freeline Therapeutics Limited
  • Gain Therapeutics, Inc.
  • GSK PLC
  • ISU ABXIS
  • JCR Pharmaceuticals Co., Ltd.
  • Lysogene
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Prevail Therapeutics by Eli Lilly and Company
  • Protalix
  • Sanofi SA
  • Shire PLC by Takeda Pharmaceutical Company Limited
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4F7A6D4FD8D1

The Type 1 Gaucher Disease Treatment Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.57 billion in 2026, with a CAGR of 11.39%, reaching USD 4.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.57 billion
Forecast Year [2032] USD 4.98 billion
CAGR (%) 11.39%

An incisive introduction that frames clinical complexity, delivery challenges, and stakeholder imperatives shaping Type 1 Gaucher disease treatment decisions

Type 1 Gaucher disease occupies a distinct place in rare disease therapeutics because it combines chronic clinical complexity with highly specialized treatment modalities. Patients rely on enzyme replacement therapies and substrate reduction approaches that demand sustained clinical oversight and integrated care pathways. As a result, clinicians, payers, and manufacturers must coordinate closely to maintain treatment continuity while addressing safety monitoring, infusion logistics, and long-term patient support needs.

The therapeutic landscape has matured from early recombinant enzyme therapies toward broader portfolios that include oral substrate reduction options and patient-centric care models such as home infusion and decentralized treatment delivery. This evolution has shifted imperatives for stakeholders: clinicians are focused on individualized treatment decisions based on disease phenotype and comorbidity profiles, payers are balancing long-term outcomes against treatment complexity, and providers are adapting to deliver high-touch care outside traditional hospital settings. Consequently, strategic planning in this therapeutic area requires a nuanced understanding of clinical evidence, delivery infrastructure, and patient experience factors.

In framing this report, emphasis is placed on actionable intelligence: how therapy choice interacts with care setting, how distribution channels impact adherence and access, and how patient age and line of therapy shape clinical decision-making. Through this lens, the introduction sets the stage for deeper analysis of disruptive shifts, tariff impacts, segmentation dynamics, regional variances, and strategic priorities for industry leaders.

How clinical innovation, decentralized delivery models, and evolving payer expectations are reshaping treatment paradigms and operational priorities in rare disease care

The therapeutic landscape for Type 1 Gaucher disease is undergoing transformative shifts driven by clinical innovation, patient-centered care delivery, and evolving regulatory and reimbursement expectations. Emerging small-molecule options have expanded oral treatment possibilities, enabling clinicians and patients to consider alternatives to lifelong infusion regimens. Parallel advances in biologics manufacturing and formulation approaches have improved supply chain robustness and product stability, which in turn enable a wider range of distribution and delivery models.

Simultaneously, there is a clear trend toward decentralizing care. Home infusion and specialty pharmacy services have grown in prominence, supported by enhanced remote monitoring tools and stronger patient support programs. These changes reduce the burden of hospital-based care and improve patient convenience, but they also create new operational demands in terms of training, cold chain logistics, and coordination with multidisciplinary care teams. Payers and health systems are increasingly evaluating total cost of care and long-term outcomes, prompting closer scrutiny of value-based arrangements and evidence generation that demonstrate sustained clinical benefit.

Looking ahead, the convergence of personalized treatment selection, flexible delivery channels, and data-driven outcomes measurement is reshaping commercial and clinical approaches. In response, stakeholders must adapt their operating models to leverage innovation, assure continuity of therapy, and align clinical evidence with payer expectations while preserving patient-centric care principles.

Operational resilience and strategic sourcing become critical as tariff changes intersect with specialized biologic and small-molecule supply chains impacting treatment delivery

The introduction of new tariff regimes in the United States for 2025 has created additional layers of operational and financial complexity for therapies that depend on international supply chains and specialized manufacturing inputs. For treatments requiring biologic production or proprietary excipients, tariff-driven cost pressures can affect procurement choices, sourcing strategies, and inventory planning. Consequently, manufacturers and their logistics partners have been reevaluating supplier diversification, nearshoring options, and contractual terms to mitigate exposure to cross-border trade shifts.

These dynamics compel organizations to strengthen their commercial and supply continuity planning. Procurement teams are increasingly engaging in scenario analysis that incorporates tariff variability and customs-related delays, while commercial functions are reassessing pricing strategies and contracting terms with payers and providers to ensure stable access for patients. At the same time, regulatory and compliance functions are coordinating more closely with trade and legal teams to navigate documentation and classification challenges that arise when product inputs cross multiple jurisdictions.

In practice, the tariff environment underscores the importance of resilient manufacturing networks, flexible distribution approaches such as home infusion and specialty pharmacy partnerships, and proactive communication with stakeholders to preserve uninterrupted therapy. As a result, operational resilience and strategic sourcing have become central to maintaining patient access and sustaining long-term commercial viability.

A multidimensional segmentation approach that links treatment modality, care setting, distribution channel, age group, and therapy line to clinical and operational implications

Segmentation provides a structured lens to interpret clinical choices and delivery patterns across Type 1 Gaucher disease therapy. Based on Treatment Type, market is studied across Enzyme Replacement Therapy and Substrate Reduction Therapy. The Enzyme Replacement Therapy is further studied across Imiglucerase, Taliglucerase Alfa, and Velaglucerase Alfa. The Substrate Reduction Therapy is further studied across Eliglustat and Miglustat. This treatment-centric segmentation clarifies how mechanism of action, administration route, and monitoring requirements influence provider selection and patient adherence.

Based on End User, market is studied across Home Care Setting, Hospital, and Infusion Center. This orientation highlights differential resource needs, training requirements, and care coordination workflows across care environments, illustrating how the same therapy can entail distinct operational models and patient experiences. Based on Distribution Channel, market is studied across Home Infusion, Hospital Pharmacy, and Specialty Pharmacy. Understanding distribution channels reveals how logistics, cold chain considerations, and reimbursement pathways interact to support continuity of therapy and patient convenience.

Based on Patient Age, market is studied across Adult and Pediatric. Age-based segmentation is essential because pediatric patients often require tailored dosing strategies, family-centered care coordination, and long-term monitoring that differs from adult care patterns. Based on Line Of Therapy, market is studied across First Line and Second Line. Line of therapy perspectives shed light on clinical decision pathways, switching considerations, and the role of real-world evidence in guiding treatment sequencing. Together, these segmentation dimensions enable rigorous assessment of clinical, operational, and access priorities.

Regional treatment delivery and access variations reveal how healthcare structures and reimbursement frameworks shape therapy uptake and care models across global regions

Geographic dynamics shape clinical practice patterns, reimbursement landscapes, and operational constraints that influence how therapies for Type 1 Gaucher disease are delivered. The Americas typically demonstrate concentrated centers of expertise and established home infusion and specialty pharmacy infrastructures that facilitate long-term management in outpatient and home settings. These regional characteristics support integrated care pathways but also necessitate robust coordination among specialty pharmacies, infusion nurses, and specialty providers.

Europe, Middle East & Africa present diverse regulatory and reimbursement environments where country-level policies and health system structures drive differential access to specific therapies and delivery models. In some health systems, centralized rare disease centers coordinate care and evidence generation, while in others decentralized networks require tailored approaches to ensure consistent treatment monitoring and adherence support. These variations influence how manufacturers prioritize market access activities and support programs.

Asia-Pacific contains a mix of highly developed healthcare markets and emerging systems that are rapidly building infrastructure for rare disease care. In this region, increasing investment in specialty care delivery, broader adoption of oral substrate reduction therapies, and growth in specialty pharmacy capabilities are notable trends. Across regions, local reimbursement frameworks, clinical guideline adoption, and distribution capacity are the primary determinants of which care models and therapeutic options gain traction.

How established biologic portfolios and emerging oral therapies are driving competitive differentiation through supply resilience, patient services, and evidence generation

Competitive dynamics in the Type 1 Gaucher disease treatment space are characterized by a mix of established biologic therapies and newer small-molecule entrants, with companies focusing on differentiating through manufacturing reliability, patient support services, and real-world evidence generation. Firms with legacy enzyme therapies continue to invest in lifecycle strategies that enhance product stability, optimize dosing convenience, and extend access through patient assistance programs. These efforts aim to preserve continuity for long-term patients while addressing emerging operational expectations from providers and payers.

Biotech and pharmaceutical innovators developing substrate reduction therapies have emphasized oral administration benefits, which can reduce the need for infusion infrastructure and potentially broaden treatment settings. These companies often prioritize outcomes research, comparative safety profiling, and adherence support to demonstrate the practical advantages of oral regimens in routine clinical care. At the same time, cross-sector partnerships between specialty pharmacies, home infusion providers, and health systems have become central to ensuring reliable distribution and patient monitoring.

Across the competitive landscape, organizations are also investing in digital patient engagement platforms, remote monitoring tools, and collaborative care models to differentiate their offerings. Strategic alliances that strengthen supply chain resilience, expand access programs, and accelerate post-approval evidence generation are recurring themes among market participants seeking to align clinical value with sustainable delivery models.

Actionable strategic priorities for aligning clinical innovation with resilient supply chains, decentralized delivery, and outcome-focused payer engagement

Leaders in the rare disease therapy space should prioritize integrated strategies that bridge clinical evidence, delivery capability, and payer alignment to secure sustainable access and optimal patient outcomes. First, invest in end-to-end supply chain resilience by diversifying sourcing, validating alternative manufacturing sites, and enhancing cold chain visibility to mitigate disruptions and tariff-related impacts. Strengthening supplier relationships and contractual flexibility will support continuity of therapy across geographies and care settings.

Second, accelerate patient-centric delivery models by expanding home infusion capabilities, partnering with specialty pharmacies, and deploying remote monitoring solutions that reduce care burden while preserving clinical oversight. Training programs for home care providers and robust patient education resources will support adherence and safety, especially among pediatric populations. Third, generate pragmatic real-world evidence that demonstrates long-term clinical benefit, safety, and quality-of-life outcomes across different lines of therapy and care settings; this evidence will be critical in reimbursement discussions and guideline adoption.

Finally, adopt flexible commercial models that accommodate diverse payer expectations and regional reimbursement frameworks, including value-based contracting where appropriate, and create targeted access pathways that reflect local system constraints. By executing on these priorities, organizations can align therapeutic innovation with operational excellence and patient-centered care.

A transparent mixed-methods research approach combining expert interviews, literature synthesis, and operational case studies to produce reproducible, actionable insights

The research underpinning this analysis combined rigorous qualitative and structured synthesis to ensure robust, actionable insights. Primary research included in-depth interviews with clinicians specializing in lysosomal storage disorders, nursing leaders managing infusion services, pharmacy directors responsible for specialty distribution, and patient advocacy representatives who provide firsthand perspectives on treatment experience and adherence barriers. These conversations were complemented by consultations with procurement, regulatory, and reimbursement experts to capture operational and policy dimensions.

Secondary research involved systematic review of peer-reviewed clinical literature, clinical guidelines, treatment safety communications, and publicly available regulatory documentation to ground the analysis in established evidence. Operational practices were examined through case studies of care delivery models and supply chain configurations. Throughout the process, cross-validation techniques were applied to reconcile stakeholder inputs with published data, and sensitivity checks were used to test the robustness of thematic conclusions.

Quality assurance included independent review by subject-matter experts and iterative refinement of findings to ensure clarity, relevance, and practical applicability for commercial, clinical, and policy audiences. The methodology emphasizes transparency and reproducibility, while enabling tailored insights for stakeholders seeking to operationalize the research findings.

Synthesis of clinical, operational, and strategic imperatives that underscore the need for aligned innovation, resilient delivery, and collaborative stakeholder engagement

In conclusion, the Type 1 Gaucher disease treatment landscape is defined by a confluence of clinical nuance, delivery innovation, and operational complexity. Therapeutic choices between enzyme replacement and substrate reduction modalities intersect with patient age, line of therapy, and care setting to create highly individualized care pathways. Meanwhile, decentralization of delivery, the maturation of specialty pharmacy ecosystems, and supply chain pressures driven by trade dynamics have intensified the need for resilient operational strategies.

Stakeholders who align clinical value with practical delivery solutions-by investing in supply chain diversification, enhancing home and specialty care infrastructure, and generating real-world evidence-will be best positioned to sustain patient access and demonstrate therapy benefits within evolving reimbursement frameworks. Importantly, collaboration across manufacturers, providers, payers, and patient groups remains central to translating therapeutic advances into meaningful improvements in patient outcomes.

This body of work synthesizes these themes into a cohesive narrative designed to inform strategic decision-making and operational planning. It underscores that durable success in this sector requires both scientific innovation and disciplined execution across the full treatment lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 1 Gaucher Disease Treatment Market, by Treatment Type

  • 8.1. Enzyme Replacement Therapy
    • 8.1.1. Imiglucerase
    • 8.1.2. Taliglucerase Alfa
    • 8.1.3. Velaglucerase Alfa
  • 8.2. Substrate Reduction Therapy
    • 8.2.1. Eliglustat
    • 8.2.2. Miglustat

9. Type 1 Gaucher Disease Treatment Market, by Patient Age

  • 9.1. Adult
  • 9.2. Pediatric

10. Type 1 Gaucher Disease Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line

11. Type 1 Gaucher Disease Treatment Market, by Distribution Channel

  • 11.1. Home Infusion
  • 11.2. Hospital Pharmacy
  • 11.3. Specialty Pharmacy

12. Type 1 Gaucher Disease Treatment Market, by End User

  • 12.1. Home Care Setting
  • 12.2. Hospital
  • 12.3. Infusion Center

13. Type 1 Gaucher Disease Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Type 1 Gaucher Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Type 1 Gaucher Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Type 1 Gaucher Disease Treatment Market

17. China Type 1 Gaucher Disease Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amicus Therapeutics, Inc.
  • 18.6. AVROBIO, Inc.
  • 18.7. CANbridge Life Sciences Ltd.
  • 18.8. CHIESI Farmaceutici S.p.A.
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Evotec SE
  • 18.11. Freeline Therapeutics Limited
  • 18.12. Gain Therapeutics, Inc.
  • 18.13. GSK PLC
  • 18.14. ISU ABXIS
  • 18.15. JCR Pharmaceuticals Co., Ltd.
  • 18.16. Lysogene
  • 18.17. Merck & Co., Inc.
  • 18.18. Pfizer Inc.
  • 18.19. Prevail Therapeutics by Eli Lilly and Company
  • 18.20. Protalix
  • 18.21. Sanofi S.A.
  • 18.22. Shire PLC by Takeda Pharmaceutical Company Limited
  • 18.23. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY IMIGLUCERASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY IMIGLUCERASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY IMIGLUCERASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TALIGLUCERASE ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TALIGLUCERASE ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TALIGLUCERASE ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY VELAGLUCERASE ALFA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY VELAGLUCERASE ALFA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY VELAGLUCERASE ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ELIGLUSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ELIGLUSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ELIGLUSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY MIGLUSTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY MIGLUSTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY MIGLUSTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY INFUSION CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY INFUSION CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY INFUSION CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GCC TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. G7 TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. NATO TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA TYPE 1 GAUCHER DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)